Pfizer's abrupt abandonment of a development deal with Celldex for the mid-stage brain cancer vaccine CDX-110 - despite positive Phase II data backing the drug - is a blow for development of drugs to treat the rare glioblastoma multiforme. On Sept. 3, Celldex announced that effective November 1, an agreement for global rights to the seemingly promising vaccine, also called rindopepimut, will be terminated.Positive Phase IIb results for the vaccine, which targets epidermal growth factor receptor III,...